Ascendis Pharma A/S 주식 주식분석 | 주식가격 | 뉴스 | ASND | US04351P1012 | A14M6X

날짜	Ascendis Pharma A/S 주식 가격
	116.00 undefined
	117.99 undefined
	117.43 undefined
	115.14 undefined
	120.04 undefined
	118.01 undefined
	120.85 undefined
	120.24 undefined
	120.50 undefined
	115.99 undefined
	117.17 undefined
	120.53 undefined
	117.26 undefined
	115.10 undefined
	115.64 undefined
	112.82 undefined
	113.10 undefined
	116.75 undefined
	119.71 undefined
	120.71 undefined
	119.88 undefined
	118.42 undefined

날짜	Ascendis Pharma A/S 매출	Ascendis Pharma A/S EBIT	Ascendis Pharma A/S 이익
2030e	4.26 조. undefined	2.42 조. undefined	2.63 조. undefined
2029e	3.19 조. undefined	1.21 조. undefined	1.9 조. undefined
2028e	2.52 조. undefined	1.34 조. undefined	1.41 조. undefined
2027e	1.91 조. undefined	864.98 백만 undefined	950.29 백만 undefined
2026e	1.05 조. undefined	238.43 백만 undefined	212.19 백만 undefined
2025e	558.99 백만 undefined	-148.23 백만 undefined	-234.43 백만 undefined
2024e	294.18 백만 undefined	-333.41 백만 undefined	-462.06 백만 undefined
2023	266.72 백만 undefined	-447.71 백만 undefined	-481.45 백만 undefined
2022	51.17 백만 undefined	-561.81 백만 undefined	-583.19 백만 undefined
2021	7.78 백만 undefined	-451.79 백만 undefined	-383.58 백만 undefined
2020	6.95 백만 undefined	-330.62 백만 undefined	-418.96 백만 undefined
2019	13.38 백만 undefined	-226.72 백만 undefined	-218.02 백만 undefined
2018	10.58 백만 undefined	-154.76 백만 undefined	-130.1 백만 undefined
2017	1.53 백만 undefined	-111.54 백만 undefined	-123.9 백만 undefined
2016	4.61 백만 undefined	-72.92 백만 undefined	-68.51 백만 undefined
2015	8.12 백만 undefined	-41.83 백만 undefined	-32.92 백만 undefined
2014	13.98 백만 undefined	-11.99 백만 undefined	-9.66 백만 undefined
2013	20.41 백만 undefined	5.28 백만 undefined	4.08 백만 undefined
2012	15.58 백만 undefined	1.51 백만 undefined	1.25 백만 undefined

	매출	EBIT	이익
2012	15.58 백만 EUR	1.51 백만 EUR	1.25 백만 EUR
2013	20.41 백만 EUR	5.28 백만 EUR	4.08 백만 EUR
2014	13.98 백만 EUR	-11.99 백만 EUR	-9.66 백만 EUR
2015	8.12 백만 EUR	-41.83 백만 EUR	-32.92 백만 EUR
2016	4.61 백만 EUR	-72.92 백만 EUR	-68.51 백만 EUR
2017	1.53 백만 EUR	-111.54 백만 EUR	-123.9 백만 EUR
2018	10.58 백만 EUR	-154.76 백만 EUR	-130.1 백만 EUR
2019	13.38 백만 EUR	-226.72 백만 EUR	-218.02 백만 EUR
2020	6.95 백만 EUR	-330.62 백만 EUR	-418.96 백만 EUR
2021	7.78 백만 EUR	-451.79 백만 EUR	-383.58 백만 EUR
2022	51.17 백만 EUR	-561.81 백만 EUR	-583.19 백만 EUR
2023	266.72 백만 EUR	-447.71 백만 EUR	-481.45 백만 EUR
2024e	294.18 백만 EUR	-333.41 백만 EUR	-462.06 백만 EUR
2025e	558.99 백만 EUR	-148.23 백만 EUR	-234.43 백만 EUR
2026e	1.05 조. EUR	238.43 백만 EUR	212.19 백만 EUR
2027e	1.91 조. EUR	864.98 백만 EUR	950.29 백만 EUR
2028e	2.52 조. EUR	1.34 조. EUR	1.41 조. EUR
2029e	3.19 조. EUR	1.21 조. EUR	1.9 조. EUR
2030e	4.26 조. EUR	2.42 조. EUR	2.63 조. EUR

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e
0.02	0.02	0.01	0.01	0	0	0.01	0.01	0.01	0.01	0.05	0.27	0.29	0.56	1.05	1.91	2.52	3.19	4.26
-	33.33	-35.00	-38.46	-50.00	-75.00	900.00	30.00	-53.85	16.67	628.57	421.57	10.53	89.80	88.35	81.92	31.96	26.56	33.32
1,480.00	1,110.00	1,707.69	2,775.00	5,550.00	22,200.00	2,220.00	1,707.69	3,700.00	57.14	76.47	83.46	75.51	39.78	21.12	11.61	8.80	6.95	5.21
0	0	0	0	0	0	0	0	0	4	39	222	0	0	0	0	0	0	0
0	0	-0.01	-0.03	-0.07	-0.12	-0.13	-0.22	-0.42	-0.38	-0.58	-0.48	-0.46	-0.23	0.21	0.95	1.41	1.9	2.63
-	300.00	-325.00	255.56	112.50	80.88	5.69	67.69	91.74	-8.37	52.22	-17.50	-3.95	-49.35	-190.60	348.11	48.21	35.16	38.26
22.94	22.94	22.94	23.77	26.56	33.63	41.09	46.51	50.62	54.77	56.07	56.29	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

14.5	19.4	50.2	119.6	180.3	195.4	277.9	592.3	718.8	682.1	735.5	399.44
5.7	1.7	1.3	1.1	0.3	0.2	0	0.8	0.4	2.2	11.9	35.87
0.4	0	1.1	1.1	1.4	2.2	2.6	4.6	6.9	21	13.7	19.9
0	0	0	0	0	0	0	0	0	75.4	130.7	208.93
0.1	0.1	0.6	3.8	2	6.9	12.4	13.4	14	25.2	31.7	38.58
20.7	21.2	53.2	125.6	184	204.7	292.9	611.1	740.1	805.9	923.5	702.72
1.2	2	1.9	2.4	2.4	2.6	4.3	45.1	108.1	126	129.1	110.63
0	0	0	0	0	0	17.1	15.5	124.5	145.9	30.4	5.69
0	0	0	0	0	0	0	0	1.4	1.8	1.9	2.13
0	0	0	0	0	0	0	0	2.2	1.8	1.3	0.92
3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5
0	0	0.1	0.3	0.3	0.3	1.2	1.5	0	0	0	0
4.7	5.5	5.5	6.2	6.2	6.4	26.1	65.6	239.7	279	166.2	122.87
0.03	0.03	0.06	0.13	0.19	0.21	0.32	0.68	0.98	1.08	1.09	0.83

0	0	0	0	0	0.01	0.01	1.13	1.74	2.12	2.12	2.13
0	0	0	0	0	0	0	0	0	0	0	0
1.2	4.9	43.5	117	172.3	0	0	-531.4	-897.2	-1,213.9	-1,860.5	-2,277.1
0	0	0	0	0	182.2	274.4	0	-0.1	3.8	3.5	0.72
0	0	0	0	0	0	0	0	0	0	0	0
1.6	6.3	45.8	120.4	176.7	187.2	280.1	597.1	838.7	905.3	263.5	-145.55
2.5	2.5	5	8.4	13.1	23.8	19.7	27.8	21.9	59.4	101	94.57
0	0	0	0	0	0	0	0	0	0	0	0
21.1	17.9	7.9	3.1	0.4	0	19.2	14.3	24	33.9	44.8	77.38
0	0	0	0	0	0	0	0	0	0	0	0
0.2	0	0	0	0	0	0	5.9	6.9	7	25.4	25.4
23.8	20.4	12.9	11.5	13.5	23.8	38.9	48	52.8	100.3	171.2	197.34
0	0	0	0	0	0	0	30.7	85.1	98	483	618.87
0	0	0	0	0	0	0	0	0	0	0	5.83
0	0	0	0	0	0	0	0.9	3.2	3	172.2	149.25
0	0	0	0	0	0	0	31.6	88.3	101	655.2	773.94
23.8	20.4	12.9	11.5	13.5	23.8	38.9	79.6	141.1	201.3	826.4	971.28
0.03	0.03	0.06	0.13	0.19	0.21	0.32	0.68	0.98	1.11	1.09	0.83

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
1	4	-9	-32	-68	-123	-130	-218	-418	-383	-583	-481
0	0	0	0	0	0	0	6	9	15	17	18
0	0	0	0	0	0	0	0	0	0	0	0
-2	0	-8	-3	4	6	5	13	0	-46	-19	-129
0	2	0	-5	10	31	4	59	191	64	153	190
0	0	0	0	0	0	0	0	1	1	9	15
0	0	0	0	0	0	0	0	-1	0	0	4
0	6	-18	-43	-60	-95	-138	-175	-271	-417	-495	-467
0	-1	0	-1	0	0	-2	-5	-21	-24	-14	-2
0	-1	0	-1	0	0	-2	-5	-291	-110	61	286
0	0	0	0	0	0	0	0	-269	-86	76	288
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	-4	-4	-6	496	125
0	0	47	114	125	133	216	529	638	357	-100	10
0	0	47	105	117	124	203	493	602	351	396	134
-	-	-	-8.00	-8.00	-8.00	-13.00	-31.00	-31.00	-	-	-1.00
0	0	0	0	0	0	0	0	0	0	0	0
-1	4	30	69	60	15	82	320	-13	-138	-1	-52
-0.94	5.11	-18.81	-44.51	-60.85	-96.04	-141.45	-181.1	-293.1	-441.88	-510.19	-469.8
0	0	0	0	0	0	0	0	0	0	0	0

Ascendis Pharma A/S 브루토마진	Ascendis Pharma A/S 이익 마진	Ascendis Pharma A/S EBIT-마진	Ascendis Pharma A/S 이익 마진
2030e	83.36 %	56.78 %	61.81 %
2029e	83.36 %	38.02 %	59.62 %
2028e	83.36 %	53.15 %	55.81 %
2027e	83.36 %	45.22 %	49.68 %
2026e	83.36 %	22.69 %	20.19 %
2025e	83.36 %	-26.52 %	-41.94 %
2024e	83.36 %	-113.34 %	-157.07 %
2023	83.36 %	-167.86 %	-180.51 %
2022	76.29 %	-1,097.93 %	-1,139.71 %
2021	54.76 %	-5,807.07 %	-4,930.33 %
2020	83.36 %	-4,757.12 %	-6,028.2 %
2019	83.36 %	-1,694.47 %	-1,629.45 %
2018	83.36 %	-1,462.76 %	-1,229.68 %
2017	83.36 %	-7,290.2 %	-8,098.04 %
2016	83.36 %	-1,581.78 %	-1,486.12 %
2015	83.36 %	-515.15 %	-405.42 %
2014	83.36 %	-85.77 %	-69.1 %
2013	83.36 %	25.87 %	19.99 %
2012	83.36 %	9.69 %	8.02 %

	브루토마진	EBIT-마진	이익 마진
2012	83.36 %	9.69 %	8.02 %
2013	83.36 %	25.87 %	19.99 %
2014	83.36 %	-85.77 %	-69.1 %
2015	83.36 %	-515.15 %	-405.42 %
2016	83.36 %	-1,581.78 %	-1,486.12 %
2017	83.36 %	-7,290.2 %	-8,098.04 %
2018	83.36 %	-1,462.76 %	-1,229.68 %
2019	83.36 %	-1,694.47 %	-1,629.45 %
2020	83.36 %	-4,757.12 %	-6,028.2 %
2021	54.76 %	-5,807.07 %	-4,930.33 %
2022	76.29 %	-1,097.93 %	-1,139.71 %
2023	83.36 %	-167.86 %	-180.51 %
2024e	83.36 %	-113.34 %	-157.07 %
2025e	83.36 %	-26.52 %	-41.94 %
2026e	83.36 %	22.69 %	20.19 %
2027e	83.36 %	45.22 %	49.68 %
2028e	83.36 %	53.15 %	55.81 %
2029e	83.36 %	38.02 %	59.62 %
2030e	83.36 %	56.78 %	61.81 %

날짜	Ascendis Pharma A/S 주당 매출	Ascendis Pharma A/S EBIT 당 주식	Ascendis Pharma A/S 주당 이익
2030e	70.2 undefined	0 undefined	43.39 undefined
2029e	52.66 undefined	0 undefined	31.39 undefined
2028e	41.61 undefined	0 undefined	23.22 undefined
2027e	31.55 undefined	0 undefined	15.67 undefined
2026e	17.33 undefined	0 undefined	3.5 undefined
2025e	9.22 undefined	0 undefined	-3.87 undefined
2024e	4.85 undefined	0 undefined	-7.62 undefined
2023	4.74 undefined	-7.95 undefined	-8.55 undefined
2022	0.91 undefined	-10.02 undefined	-10.4 undefined
2021	0.14 undefined	-8.25 undefined	-7 undefined
2020	0.14 undefined	-6.53 undefined	-8.28 undefined
2019	0.29 undefined	-4.87 undefined	-4.69 undefined
2018	0.26 undefined	-3.77 undefined	-3.17 undefined
2017	0.05 undefined	-3.32 undefined	-3.68 undefined
2016	0.17 undefined	-2.75 undefined	-2.58 undefined
2015	0.34 undefined	-1.76 undefined	-1.38 undefined
2014	0.61 undefined	-0.52 undefined	-0.42 undefined
2013	0.89 undefined	0.23 undefined	0.18 undefined
2012	0.68 undefined	0.07 undefined	0.05 undefined

	주당 매출	EBIT 당 주식	주당 이익
2012	0.68 EUR	0.07 EUR	0.05 EUR
2013	0.89 EUR	0.23 EUR	0.18 EUR
2014	0.61 EUR	-0.52 EUR	-0.42 EUR
2015	0.34 EUR	-1.76 EUR	-1.38 EUR
2016	0.17 EUR	-2.75 EUR	-2.58 EUR
2017	0.05 EUR	-3.32 EUR	-3.68 EUR
2018	0.26 EUR	-3.77 EUR	-3.17 EUR
2019	0.29 EUR	-4.87 EUR	-4.69 EUR
2020	0.14 EUR	-6.53 EUR	-8.28 EUR
2021	0.14 EUR	-8.25 EUR	-7 EUR
2022	0.91 EUR	-10.02 EUR	-10.4 EUR
2023	4.74 EUR	-7.95 EUR	-8.55 EUR
2024e	4.85 EUR	0 EUR	-7.62 EUR
2025e	9.22 EUR	0 EUR	-3.87 EUR
2026e	17.33 EUR	0 EUR	3.5 EUR
2027e	31.55 EUR	0 EUR	15.67 EUR
2028e	41.61 EUR	0 EUR	23.22 EUR
2029e	52.66 EUR	0 EUR	31.39 EUR
2030e	70.2 EUR	0 EUR	43.39 EUR

날짜	CHINA	North America
2021	922,000 EUR	6.86 백만 EUR

	CHINA	North America
2021	922,000 EUR	6.86 백만 EUR

	주식 수량
2012	22.94 백만 Aktien
2013	22.94 백만 Aktien
2014	22.94 백만 Aktien
2015	23.77 백만 Aktien
2016	26.56 백만 Aktien
2017	33.63 백만 Aktien
2018	41.09 백만 Aktien
2019	46.51 백만 Aktien
2020	50.62 백만 Aktien
2021	54.77 백만 Aktien
2022	56.07 백만 Aktien
2023	56.29 백만 Aktien
2024e	56.29 백만 Aktien
2025e	56.29 백만 Aktien
2026e	56.29 백만 Aktien
2027e	56.29 백만 Aktien
2028e	56.29 백만 Aktien
2029e	56.29 백만 Aktien
2030e	56.29 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-1.44	-1.91 (-32.32 %)	2024 Q2
-1.53	-2.3 (-50.09 %)	2024 Q1
-2.07	-1.54 (25.51 %)	2023 Q4
-2.43	-2.88 (-18.71 %)	2023 Q3
-2.64	-2.16 (18.26 %)	2023 Q2
-2.71	-1.98 (27.04 %)	2023 Q1
-2.61	-3.7 (-41.66 %)	2022 Q4
-2.54	-3.03 (-19.31 %)	2022 Q3
-2.18	-1.46 (32.87 %)	2022 Q2
-2.04	-2.21 (-8.34 %)	2022 Q1
-2.39	-1.87 (21.72 %)	2021 Q4
-2.34	-1.47 (37.16 %)	2021 Q3
-2.27	-2.5 (-10.14 %)	2021 Q2
-1.74	-1.17 (32.73 %)	2021 Q1
-1.58	-2.64 (-66.91 %)	2020 Q4
-1.61	-2.31 (-43.8 %)	2020 Q3
-1.48	-1.97 (-32.96 %)	2020 Q2
-1.38	-1.32 (4.01 %)	2020 Q1
-1.49	-1.7 (-14.18 %)	2019 Q4
-1.21	-0.53 (56.3 %)	2019 Q3
-1.23	-1.25 (-1.41 %)	2019 Q2
-1.02	-1.24 (-21.37 %)	2019 Q1
-1.02	-0.76 (25.67 %)	2018 Q4
-1.08	-0.81 (25.33 %)	2018 Q3
-0.92	-0.55 (40.03 %)	2018 Q2
-0.77	-1.07 (-38.71 %)	2018 Q1
-0.83	-0.92 (-11.43 %)	2017 Q4
-0.75	-1.04 (-38.69 %)	2017 Q3
-0.74	-0.94 (-26.63 %)	2017 Q2
-0.68	-0.78 (-14.65 %)	2017 Q1
-0.58	-0.62 (-6.91 %)	2016 Q4
-0.66	-0.72 (-9.44 %)	2016 Q3
-0.63	-0.53 (15.73 %)	2016 Q2
-0.53	-0.82 (-53.75 %)	2016 Q1
-0.42	-0.49 (-16.31 %)	2015 Q4
-0.55	-0.3 (46.16 %)	2015 Q3
-0.44	-0.63 (-43.61 %)	2015 Q2
-0.36	0.06 (117.4 %)	2015 Q1

%-지분	이름	주식	변경
16.66953 %	RA Capital Management, LP	10,108,400	0
8.18408 %	Westfield Capital Management Company, L.P.	4,962,824	887,610
7.57589 %	Fidelity Management & Research Company LLC	4,594,018	-15,506
7.08283 %	Artisan Partners Limited Partnership	4,295,029	-1,376,905
6.92062 %	Avoro Capital Advisors LLC	4,196,661	229,995
6.46242 %	Janus Henderson Investors	3,918,813	151,610
4.30880 %	Wellington Management Company, LLP	2,612,856	-133,016
3.47015 %	Capital International Investors	2,104,298	-87,014
2.94220 %	T. Rowe Price Associates, Inc.	1,784,148	2,222
2.81879 %	MFS Investment Management	1,709,315	92,577
2.70955 %	Capital Research Global Investors	1,643,074	0
2.17389 %	Franklin Advisers, Inc.	1,318,244	127,711
1.75385 %	Invesco Advisers, Inc.	1,063,536	151,825
1.35309 %	Adage Capital Management, L.P.	820,512	611,000
1.26375 %	Putnam Investment Management, L.L.C.	766,339	-19,729
1.23681 %	Vestal Point Capital, LP	750,000	225,000
1.21089 %	Sofinnova Investments, Inc	734,284	-19,748
1.09549 %	Paradigm BioCapital Advisors LP	664,307	156,355
1.09315 %	Spyglass Capital Management LLC	662,888	48,781
1.08948 %	Columbia Threadneedle Investments (US)	660,662	605,496
0.98337 %	TimesSquare Capital Management, LLC	596,314	20,616
0.88681 %	Citadel Advisors LLC	537,762	80,258
0.86721 %	Medical Strategy GmbH	525,874	6,780
0.78937 %	Brown Advisory	478,676	-205,396
0.78331 %	AllianceBernstein L.P.	475,001	1,248
0.78075 %	Millennium Management LLC	473,449	111,389
0.75416 %	Two Sigma Investments, LP	457,320	81,720
0.73367 %	Capital World Investors	444,896	0
0.72973 %	Fidelity International	442,508	431,781
0.69802 %	Mikkelsen Jan Moller	423,279	423,279
0.69517 %	Goldman Sachs & Company, Inc.	421,551	-15,541
0.59803 %	BlackRock Institutional Trust Company, N.A.	362,645	-1,838
0.57094 %	Voloridge Investment Management, LLC	346,218	38,719
0.54178 %	Fidelity Institutional Asset Management	328,537	-400
0.51047 %	The Vanguard Group, Inc.	309,552	0
0.50639 %	Fred Alger Management, LLC	307,073	120,952
0.50457 %	American Century Investment Management, Inc.	305,974	-167
0.47823 %	Rock Springs Capital Management LP	290,000	0
0.46559 %	Candriam Luxembourg S.A.	282,331	0
0.46428 %	D. E. Shaw & Co., L.P.	281,537	-58,581
0.43630 %	SEI Investments Management Corporation	264,571	-81,615
0.43389 %	ARS Investment Partners LLC	263,111	9,972
0.39128 %	BofA Global Research (US)	237,273	-17,107
0.38534 %	Summit Partners Public Asset Management, LLC	233,673	8,562
0.37560 %	Tri Locum Partners LP	227,762	115,092
0.36190 %	Q Global Advisors, LLC	219,459	-65,541
0.32778 %	Woodline Partners LP	198,766	2,736
0.32214 %	Candriam Belgium S.A.	195,347	95,972
0.31212 %	Finepoint Capital LP	189,272	13,600
0.30769 %	First Turn Management, LLC	186,581	34,994
0.29853 %	DWS Investment GmbH	181,029	-80,000
0.29571 %	New York State Common Retirement Fund	179,318	-20,083
0.26928 %	Norges Bank Investment Management (NBIM)	163,290	163,290
0.26898 %	BNP Paribas Asset Management USA, Inc.	163,110	76,908
0.26618 %	Allspring Global Investments, LLC	161,410	-17,842
0.26486 %	Rice Hall James & Associates, LLC	160,614	8,958
0.26091 %	abrdn Inc.	158,213	-2,389
0.24130 %	Pictet Asset Management Ltd.	146,327	-124,443
0.23444 %	Acadian Asset Management LLC	142,165	-108,327
0.22165 %	Victory Capital Management Inc.	134,409	-155
0.21562 %	Pictet Asset Management (Japan) Ltd.	130,751	49,552
0.21120 %	BNP Paribas Securities Corp. North America	128,074	52,534
0.20052 %	Loomis, Sayles & Company, L.P.	121,594	113,829
0.18672 %	Saturn V Capital Management LP	113,224	9,796
0.16672 %	Invus Public Equities Advisors, LLC	101,100	101,100
0.16505 %	Morgan Stanley & Co. LLC	100,086	15,919
0.16491 %	Soros Fund Management, L.L.C.	100,000	96,568
0.16482 %	TD Asset Management Inc.	99,946	-136,924
0.16184 %	Schonfeld Strategic Advisors LLC	98,141	-3,859
0.14397 %	Harbor Capital Advisors, Inc.	87,302	35,102
0.14301 %	Ghost Tree Capital, LLC	86,721	86,721
0.13423 %	Driehaus Capital Management, LLC	81,396	-18,924
0.13353 %	Dafna Capital Management, LLC	80,972	-11,500
0.12918 %	Principal Global Investors (Equity)	78,334	-7,283
0.12903 %	Thrivent Asset Management, LLC	78,245	-36,156
0.12383 %	Mellon Investments Corporation	75,093	-35,108
0.11720 %	Baillie Gifford & Co.	71,071	-10,135
0.09894 %	Alyeska Investment Group, L.P.	60,000	60,000
0.09529 %	Geode Capital Management, L.L.C.	57,786	1,684
0.09412 %	AEGON Investment Management B.V.	57,076	2,920
0.09028 %	Qube Research & Technologies Ltd	54,748	54,748
0.08526 %	Gray Foundation	51,700	0
0.08454 %	Adar1 Capital Management LLC	51,263	2,679
0.08245 %	Altium Capital Management LP	50,000	25,000
0.07919 %	Goldman Sachs Asset Management International	48,019	0
0.07868 %	Manulife Investment Management (North America) Limited	47,712	-6,814
0.07751 %	Resolute Capital Asset Partners LLC	47,000	0
0.07407 %	Schroder Investment Management Ltd. (SIM)	44,918	44,918
0.06914 %	Diversified Trust Company	41,924	41,924
0.05963 %	First Light Asset Management, LLC	36,157	36,157
0.05781 %	State Street Global Advisors (US)	35,057	705
0.05664 %	INVESCO Asset Management Limited	34,346	-10,124
0.05558 %	Parametric Portfolio Associates LLC	33,704	-5,315
0.05555 %	Matisse Capital	33,684	-1,045
0.05504 %	Tudor Investment Corporation	33,375	33,375
0.05435 %	BlackRock Advisors (UK) Limited	32,957	693
0.05435 %	BlackRock Asset Management Ireland Limited	32,957	2,018
0.05040 %	T. Rowe Price Investment Management, Inc.	30,564	-2,538,339
0.04996 %	Neuberger Berman, LLC	30,296	30,296
0.04995 %	Marshall Wace LLP	30,289	5,205

What values and corporate philosophy does Ascendis Pharma A/S represent?

Ascendis Pharma A/S represents values of innovation, patient focus, and scientific excellence. The company is dedicated to transforming the lives of patients with rare diseases through its cutting-edge technologies and research. Ascendis Pharma takes a patient-centric approach by developing targeted therapies that address unmet medical needs. With a steadfast commitment to scientific rigor, the company aims to advance the understanding and treatment of rare diseases. Ascendis Pharma's corporate philosophy encompasses a culture of collaboration, integrity, and a drive for continuous improvement. By prioritizing the well-being of patients and staying at the forefront of scientific advancements, Ascendis Pharma A/S strives to make a positive impact in the healthcare industry.

In which countries and regions is Ascendis Pharma A/S primarily present?

Ascendis Pharma A/S is primarily present in the United States and Europe, including countries such as Denmark, Germany, and Switzerland.

What significant milestones has the company Ascendis Pharma A/S achieved?

Ascendis Pharma A/S has achieved several significant milestones. The company successfully developed and obtained regulatory approval for their innovative TransCon technology platform. This platform enables the production of long-acting prodrug therapies that offer improved treatment options for patients. Ascendis Pharma A/S also advanced its pipeline of therapeutic candidates, including its lead product, TransCon hGH, for the treatment of growth hormone deficiency. Additionally, the company has formed strategic collaborations with major pharmaceutical companies, further validating their innovative approach. These milestones demonstrate Ascendis Pharma A/S's commitment to advancing medical science and improving patient outcomes.

What is the history and background of the company Ascendis Pharma A/S?

Ascendis Pharma A/S is a reputable biopharmaceutical company headquartered in Denmark. Established in 2006, Ascendis Pharma is dedicated to developing innovative therapies for rare endocrine diseases. The company focuses on utilizing its proprietary TransCon technology platform, which enables the creation of long-acting therapies, to improve patient outcomes. Ascendis Pharma has a strong portfolio of product candidates, including TransCon hGH for growth hormone deficiency and TransCon PTH for hypoparathyroidism. With a commitment to revolutionizing treatment options, Ascendis Pharma continues to make significant strides in the field of endocrinology, enhancing the lives of patients worldwide.

Who are the main competitors of Ascendis Pharma A/S in the market?

The main competitors of Ascendis Pharma A/S in the market include other pharmaceutical companies such as Novo Nordisk A/S, Amgen Inc., and Eli Lilly and Company. These companies operate in the same healthcare sector and often develop and market similar medical products and treatments. Ascendis Pharma A/S faces competition from these companies in terms of research and development, innovation, and market presence. However, Ascendis Pharma A/S has established itself as a reputable player in the industry through its unique products and differentiated approach in addressing unmet medical needs.

In which industries is Ascendis Pharma A/S primarily active?

Ascendis Pharma A/S is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Ascendis Pharma A/S?

The business model of Ascendis Pharma A/S revolves around the development and commercialization of innovative therapies to address unmet medical needs. The company focuses on utilizing its proprietary TransCon technology platform to create prodrug versions of existing drugs that aim to improve their efficacy and therapeutic profile. Ascendis Pharma aims to target rare and serious conditions, particularly in endocrinology and orphan diseases. By combining its deep expertise in medical research and development with strategic partnerships and collaborations, Ascendis Pharma is dedicated to bringing transformative treatment options to patients worldwide.

Ascendis Pharma A/S 2024의 P/E 비율은 얼마입니까?

Ascendis Pharma A/S의 P/E 비율은 -14.13입니다.

Ascendis Pharma A/S 2024의 KUV는 얼마입니까?

Ascendis Pharma A/S의 P/S 비율은 22.19입니다.

Ascendis Pharma A/S의 AlleAktien 품질 점수는 얼마인가요?

Ascendis Pharma A/S에 대한 AlleAktien 품질 점수는 6/10입니다.

Ascendis Pharma A/S 2024의 매출은 얼마인가요?

예상되는 Ascendis Pharma A/S 매출은 294.18 백만 EUR입니다.

Ascendis Pharma A/S 2024의 이익은 얼마인가요?

예상되는 Ascendis Pharma A/S 이익은 -462.06 백만 EUR입니다.

Ascendis Pharma A/S은 무엇을 하나요?

Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative therapies for rare diseases. The company's business model is based on utilizing its proprietary TransCon technology platform, which consists of a combination of prodrug and carrier systems to achieve an extended drug profile. The TransCon system allows Ascendis Pharma's products to have a long half-life and controlled release, resulting in increased effectiveness and a better safety profile. The company operates in three main areas: 1. Endocrinology Ascendis Pharma focuses on developing therapies for rare endocrine diseases. The company has a pipeline of several products in various stages of clinical development targeting growth hormone deficiency, hypoparathyroidism, and hypophysitis. The leading product in Ascendis Pharma's endocrinology pipeline is TransCon HGH, a weekly administered growth hormone for individuals with growth hormone deficiency. The product is currently in Phase III of clinical development. 2. Oncology In oncology, Ascendis Pharma focuses on developing therapies for cancer treatment. The company has a pipeline of products in various stages of clinical development targeting solid tumors and hematologic malignancies. The leading product in Ascendis Pharma's oncology pipeline is TransCon PTH, a novel therapy for patients with bone metastasis from breast cancer. The product is currently in Phase I of clinical development. 3. Immunology In the immunology category, Ascendis Pharma focuses on developing therapies for rare immune-related diseases. The pipeline includes products in various stages of clinical development, including primary immunodeficiencies, autoimmune diseases, allergies, and inflammatory diseases. The leading product in Ascendis Pharma's immunology pipeline is TransCon CNP, a novel therapy for patients with vasculitis, an inflammatory disease that affects blood vessels. The product is currently in Phase I of clinical development. Ascendis Pharma has a strong pipeline and is well-positioned to benefit from its TransCon technology platform and grow as a leading provider of innovative therapies for rare diseases. Continuous development of new products is expected to ensure long-term growth within the company.

Ascendis Pharma A/S 배당금은 얼마입니까?

Ascendis Pharma A/S은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Ascendis Pharma A/S이 얼마나 자주 배당을 지급하나요?

Ascendis Pharma A/S의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Ascendis Pharma A/S ISIN이 무엇입니까?

Ascendis Pharma A/S의 ISIN은 US04351P1012입니다.

Ascendis Pharma A/S WKN은 무엇인가요?

Ascendis Pharma A/S의 WKN은 A14M6X입니다.

Ascendis Pharma A/S 티커는 무엇인가요?

Ascendis Pharma A/S의 티커는 ASND입니다.

Ascendis Pharma A/S이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Ascendis Pharma A/S은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Ascendis Pharma A/S은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Ascendis Pharma A/S의 배당 수익률은 얼마입니까?

Ascendis Pharma A/S의 현재 배당 수익률은 입니다.

Ascendis Pharma A/S의 배당금은 언제 지급되나요?

Ascendis Pharma A/S은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Ascendis Pharma A/S의 배당금은 얼마나 안전한가요?

Ascendis Pharma A/S은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Ascendis Pharma A/S의 배당금은 얼마입니까?

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Ascendis Pharma A/S이(가) 속해 있는 섹터는 어디인가요?

Ascendis Pharma A/S은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Ascendis Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

Ascendis Pharma A/S의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Ascendis Pharma A/S의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Ascendis Pharma A/S의 2023년도 배당금은 얼마였습니까?

2023년에 Ascendis Pharma A/S는 0 EUR를 배당금으로 지급했습니다.

Ascendis Pharma A/S는 어떤 화폐로 배당금을 지급하나요?

Ascendis Pharma A/S의 배당금은 EUR에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	Ascendis Pharma A/S 티커
프랑크푸르트	A71.F
뮌헨	A71.MU
NASDAQ	ASND

Ascendis Pharma A/S 티커	Ascendis Pharma A/S FIGI
ASND:US	BBG007R7VNC1
ASND:UA	BBG007R7VND0
ASND:UC	BBG007R7VNF8
ASND:UN	BBG007R7VNH6
ASND:UP	BBG007R7VNJ4
ASND:UB	BBG007R7VNM0
ASND:UM	BBG007R7VNP7
ASND:UX	BBG007R7VNQ6
ASND:UD	BBG007R7VNY7
ASND:UW	BBG007R7VP18
ASND:UF	BBG007R7VP27
ASND:VY	BBG007R7VP36
ASND:VJ	BBG007R7VP45
ASND:VK	BBG007R7VP54
A71:GR	BBG0081KSJY7
A71:GF	BBG0081KSJZ6
A71:GS	BBG0081KSK29
A71:GM	BBG0081KSK38
A71:GB	BBG0081KSK47
ASND:VF	BBG00DJH0K17
ASNDN:MM	BBG00J6GLB62
ASNDN:MF	BBG00J6GLB71
ASNDN:MU	BBG00JX0QX19
ASNDUSD:X2	BBG00K6RQTF1
ASNDUSD:XB	BBG00K6RQTG0
ASNDUSD:XH	BBG00K6RQTJ7
ASNDUSD:XF	BBG00K6RQTL4
ASNDUSD:XE	BBG00K6RQTN2
ASNDUSD:XJ	BBG00K6RQTP0
ASNDUSD:XL	BBG00K6RQTQ9
ASNDUSD:XG	BBG00K6RQTR8
ASNDUSD:XO	BBG00K6RQTS7
ASNDUSD:XS	BBG00K6RQTX1
ASNDUSD:XA	BBG00K6RQTY0
ASNDUSD:E1	BBG00K6RQTZ9
ASNDUSD:XT	BBG00K6RQV02
ASNDUSD:XW	BBG00K6RQV11
ASNDUSD:XU	BBG00K6RQV20
ASNDUSD:XV	BBG00K6RQV39
ASNDUSD:XM	BBG00K6RQV48
ASNDUSD:XQ	BBG00K6RQV66
ASNDUSD:XX	BBG00K6RQV75
ASNDUSD:XZ	BBG00K6RQV84
ASNDUSD:EU	BBG00K6RQVB0
ASNDGBP:XS	BBG00L8QRGG5
ASNDGBP:XH	BBG00L8QRGK0
ASNDGBP:XF	BBG00L8QRGM8
ASNDGBP:XE	BBG00L8QRGP5
ASNDGBP:XJ	BBG00L8QRGQ4
ASNDGBP:XL	BBG00L8QRGR3
ASNDGBP:XG	BBG00L8QRGS2
ASNDGBP:XO	BBG00L8QRGT1
ASNDGBP:XA	BBG00L8QRGY5
ASNDGBP:E1	BBG00L8QRGZ4
ASNDGBP:XT	BBG00L8QRH00
ASNDGBP:XW	BBG00L8QRH19
ASNDGBP:XU	BBG00L8QRH28
ASNDGBP:XV	BBG00L8QRH37
ASNDGBP:XM	BBG00L8QRH46
ASNDGBP:XQ	BBG00L8QRH55
ASNDGBP:XX	BBG00L8QRH64
ASNDGBP:XZ	BBG00L8QRH73
ASNDGBP:EU	BBG00L8QRH91
ASNDUSD:EP	BBG00RPM9XB0
ASNDUSD:EZ	BBG00RPM9XD8
ASND:VG	BBG00X1P96R8
ASND:VP	BBG00X1SQM34
A71:LA	BBG018H9CT79
A71:LU	BBG018J30V05
A71:GZ	BBG01KN4QH68

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커ASND

ISINUS04351P1012

WKNA14M6X

Ascendis Pharma A/S 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Ascendis Pharma A/S 주가 이력

Ascendis Pharma A/S 주식 매출, EBIT, 이익 US04351P1012 · A14M6X

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Ascendis Pharma A/S 매출, 이익 및 EBIT 역사

Ascendis Pharma A/S 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Ascendis Pharma A/S 주식 마진 US04351P1012 · A14M6X

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Ascendis Pharma A/S 마진 역사

Ascendis Pharma A/S 주식 매출, EBIT, 주당 순이익 US04351P1012 · A14M6X

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Ascendis Pharma A/S 매출, 이익 및 EBIT 주당 역사

Ascendis Pharma A/S 주식 및 주식 분석

Ascendis Pharma A/S 지역별 매출 US04351P1012 · A14M6X

세그먼트별 매출

지역별 매출 개요

해석 및 사용법

투자 전략

Ascendis Pharma A/S 매출 세분화

한눈에 과소평가된 주식을 인식하세요.

Ascendis Pharma A/S Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Ascendis Pharma A/S 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Ascendis Pharma A/S 주식 수량 US04351P1012 · A14M6X

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

Ascendis Pharma A/S 수익 예상

Ascendis Pharma A/S 수익 놀라움

Eulerpool ESG Scorecard© Ascendis Pharma A/S 주식을 위해

Eulerpool World ESG Rating (EESG©)

티커
ASND

ISIN
US04351P1012

WKN
A14M6X